ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)

Publication | Closed Access

DOI

Citations

References

2025

Year

M. Roupret, Aurélie Bertaut, G. Pignot, Y. Neuzillet, N. Houede, R. Mathieu, L. Corbel, D. Besson, T. Seisen, L. Jaffrelot,

Annals of Oncology